Arbutus Biopharma Corp Company Profile (NASDAQ:ABUS)

About Arbutus Biopharma Corp (NASDAQ:ABUS)

Arbutus Biopharma Corp logoArbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. The Company's lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, cccDNA epigenetic modifiers and stimulator of interferon genes agonists.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ABUS
  • CUSIP: N/A
  • Web: www.arbutusbio.com
Capitalization:
  • Market Cap: $184.33 million
  • Outstanding Shares: 55,024,000
Average Prices:
  • 50 Day Moving Avg: $3.39
  • 200 Day Moving Avg: $2.94
  • 52 Week Range: $2.35 - $4.49
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.41
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $1.12 million
  • Price / Sales: 164.58
  • Book Value: $3.44 per share
  • Price / Book: 0.97
Profitability:
  • EBIDTA: ($68,410,000.00)
  • Net Margins: -1,192.92%
  • Return on Equity: -8.50%
  • Return on Assets: -6.68%
Debt:
  • Current Ratio: 18.09%
  • Quick Ratio: 18.09%
Misc:
  • Average Volume: 235,531 shs.
  • Beta: 1.24
  • Short Ratio: 8.76
 

Frequently Asked Questions for Arbutus Biopharma Corp (NASDAQ:ABUS)

What is Arbutus Biopharma Corp's stock symbol?

Arbutus Biopharma Corp trades on the NASDAQ under the ticker symbol "ABUS."

How were Arbutus Biopharma Corp's earnings last quarter?

Arbutus Biopharma Corp (NASDAQ:ABUS) released its earnings results on Thursday, May, 4th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.30) by $0.04. The company earned $0.20 million during the quarter, compared to analyst estimates of $7.50 million. Arbutus Biopharma Corp had a negative return on equity of 8.50% and a negative net margin of 1,192.92%. View Arbutus Biopharma Corp's Earnings History.

When will Arbutus Biopharma Corp make its next earnings announcement?

Arbutus Biopharma Corp is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for Arbutus Biopharma Corp.

Where is Arbutus Biopharma Corp's stock going? Where will Arbutus Biopharma Corp's stock price be in 2017?

6 equities research analysts have issued 12 month price targets for Arbutus Biopharma Corp's stock. Their predictions range from $5.00 to $10.00. On average, they expect Arbutus Biopharma Corp's stock price to reach $7.00 in the next year. View Analyst Ratings for Arbutus Biopharma Corp.

What are analysts saying about Arbutus Biopharma Corp stock?

Here are some recent quotes from research analysts about Arbutus Biopharma Corp stock:

  • 1. Wedbush analysts commented, "We believe ABUS remains undervalued ahead of key clinical readouts in 2017 for its HBV pipeline candidates, a mid:17 readout of Alnylam's Ph 3 patisiran study in ATTR that could lead to a significant royalties to ABUS, and the potential for additional partnerships around its attractive LNP platform." (3/22/2017)
  • 2. According to Zacks Investment Research, "Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC. " (2/17/2017)

Who are some of Arbutus Biopharma Corp's key competitors?

Who are Arbutus Biopharma Corp's key executives?

Arbutus Biopharma Corp's management team includes the folowing people:

  • Vivek Ramaswamy, Chairman of the Board
  • Mark J. Murray Ph.D., President, Chief Executive Officer, Director
  • Bruce G. Cousins, Chief Financial Officer, Executive Vice President
  • Elizabeth Howard, Executive Vice President, General Counsel
  • Peter Lutwyche Ph.D., Chief Technology Officer
  • Michael Joseph Sofia, Chief Scientific Officer
  • William Thomas Symonds III, Chief Development Officer, Director
  • Michael J. Abrams Ph.D., Managing Director - Non-HBV Assets
  • Patrick T. Higgins, Chief Business Officer
  • Daniel D. Burgess, Director

Who owns Arbutus Biopharma Corp stock?

Arbutus Biopharma Corp's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Primecap Management Co. CA (0.00%), Bank of Montreal Can (0.00%), AXA (0.00%), K2 Principal Fund L.P. (0.00%), Morgan Stanley (0.00%) and Goldman Sachs Group Inc. (0.44%). View Institutional Ownership Trends for Arbutus Biopharma Corp.

Who sold Arbutus Biopharma Corp stock? Who is selling Arbutus Biopharma Corp stock?

Arbutus Biopharma Corp's stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Oxford Asset Management, Bank of Montreal Can, K2 Principal Fund L.P., Ameriprise Financial Inc. and Credit Suisse AG. View Insider Buying and Selling for Arbutus Biopharma Corp.

Who bought Arbutus Biopharma Corp stock? Who is buying Arbutus Biopharma Corp stock?

Arbutus Biopharma Corp's stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Morgan Stanley, Primecap Management Co. CA, AXA and Vanguard Group Inc.. View Insider Buying and Selling for Arbutus Biopharma Corp.

How do I buy Arbutus Biopharma Corp stock?

Shares of Arbutus Biopharma Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arbutus Biopharma Corp's stock price today?

One share of Arbutus Biopharma Corp stock can currently be purchased for approximately $3.35.


MarketBeat Community Rating for Arbutus Biopharma Corp (NASDAQ ABUS)
Community Ranking:  3.5 out of 5 (   )
Outperform Votes:  162 (Vote Outperform)
Underperform Votes:  69 (Vote Underperform)
Total Votes:  231
MarketBeat's community ratings are surveys of what our community members think about Arbutus Biopharma Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Arbutus Biopharma Corp (NASDAQ:ABUS) (?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $7.00 (108.96% upside)

Analysts' Ratings History for Arbutus Biopharma Corp (NASDAQ:ABUS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/4/2017Chardan CapitalUpgradeNeutral -> Buy$3.00 -> $6.00HighView Rating Details
3/22/2017WedbushReiterated RatingOutperform$9.00 -> $10.00LowView Rating Details
1/9/2017Bloom BurtonUpgradeAccumulate -> BuyN/AView Rating Details
11/6/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
8/21/2016William BlairReiterated RatingOutperformN/AView Rating Details
8/17/2016Leerink SwannDowngradeOutperform -> Market PerformN/AView Rating Details
12/21/2015Royal Bank of CanadaLower Price Target$20.00 -> $12.00N/AView Rating Details
6/16/2015Maxim GroupLower Price TargetHold -> Buy$27.00 -> $14.00N/AView Rating Details
(Data available from 5/29/2015 forward)

Earnings

Earnings History for Arbutus Biopharma Corp (NASDAQ:ABUS)
Earnings by Quarter for Arbutus Biopharma Corp (NASDAQ:ABUS)
Earnings History by Quarter for Arbutus Biopharma Corp (NASDAQ:ABUS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2017        
5/4/20173/31/2017($0.30)($0.34)$7.50 million$0.20 millionViewListenView Earnings Details
11/5/2015Q3 2015($0.31)($0.42)$3.37 million$4.10 millionViewN/AView Earnings Details
8/5/2015Q2($0.25)($0.20)$3.77 million$3.40 millionViewN/AView Earnings Details
3/12/2015Q4 2014($0.32)($0.27)$6.12 million$4.40 millionViewN/AView Earnings Details
11/6/2014Q314($0.40)($0.39)$3.71 million$4.40 millionViewN/AView Earnings Details
8/14/2014Q214($0.13)($0.11)$3.72 million$1.80 millionViewN/AView Earnings Details
12/18/2013Q3($0.07)($0.12)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Arbutus Biopharma Corp (NASDAQ:ABUS)
2017 EPS Consensus Estimate: ($1.54)
2018 EPS Consensus Estimate: ($1.20)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.38)($0.25)($0.30)
Q2 20173($0.42)($0.39)($0.40)
Q3 20173($0.43)($0.39)($0.41)
Q4 20173($0.44)($0.39)($0.42)
Q1 20181($0.30)($0.30)($0.30)
Q2 20181($0.30)($0.30)($0.30)
Q3 20181($0.31)($0.31)($0.31)
Q4 20181($0.29)($0.29)($0.29)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Arbutus Biopharma Corp (NASDAQ:ABUS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Arbutus Biopharma Corp (NASDAQ:ABUS)
Insider Ownership Percentage: 9.20%
Institutional Ownership Percentage: 61.24%
Insider Trades by Quarter for Arbutus Biopharma Corp (NASDAQ:ABUS)
Institutional Ownership by Quarter for Arbutus Biopharma Corp (NASDAQ:ABUS)
Insider Trades by Quarter for Arbutus Biopharma Corp (NASDAQ:ABUS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/24/2015Richard C Henriques JrDirectorBuy1,000$6.95$6,950.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Arbutus Biopharma Corp (NASDAQ:ABUS)
Latest Headlines for Arbutus Biopharma Corp (NASDAQ:ABUS)
Source:
DateHeadline
globenewswire.com logoArbutus Presents HBV Drug Combination Studies at ICAR - GlobeNewswire (press release)
globenewswire.com - May 23 at 5:31 AM
finance.yahoo.com logoArbutus Presents HBV Drug Combination Studies at ICAR
finance.yahoo.com - May 22 at 3:19 PM
finance.yahoo.com logoModerna Can't Escape My Intellectual Property, Says Arbutus CEO
finance.yahoo.com - May 16 at 3:17 PM
americanbankingnews.com logoArbutus Biopharma Corp (ABUS) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - May 15 at 12:47 PM
finance.yahoo.com logoArbutus Biopharma Corp. :ABUS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017
finance.yahoo.com - May 10 at 3:25 PM
bizjournals.com logo$10M move: How a company out to cure hepatitis B ended up in Warminster
www.bizjournals.com - May 9 at 3:18 PM
americanbankingnews.com logoArbutus Biopharma Corp (ABUS) Forecasted to Post Q1 2018 Earnings of ($0.30) Per Share
www.americanbankingnews.com - May 8 at 11:14 AM
americanbankingnews.com logoArbutus Biopharma Corp (ABUS) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS
www.americanbankingnews.com - May 5 at 3:58 PM
finance.yahoo.com logoEdited Transcript of ABUS earnings conference call or presentation 4-May-17 8:30pm GMT
finance.yahoo.com - May 5 at 3:17 PM
seekingalpha.com logoArbutus Biopharma's (ABUS) CEO Mark Murray on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 4 at 8:19 PM
finance.yahoo.com logoArbutus Announces Corporate Update and First Quarter 2017 Financial Results
finance.yahoo.com - May 4 at 8:19 PM
finance.yahoo.com logoInvestor Network: Arbutus Biopharma Corporation to Host Earnings Call
finance.yahoo.com - May 4 at 3:18 PM
americanbankingnews.com logoArbutus Biopharma Corp (ABUS) Receives News Sentiment Score of 0.12
www.americanbankingnews.com - May 3 at 8:28 AM
finance.yahoo.com logoArbutus Announces Conference Call to Provide a Corporate Update and First Quarter 2017 Financial Results
finance.yahoo.com - May 2 at 3:22 PM
americanbankingnews.com logoArbutus Biopharma Corp (ABUS) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - April 30 at 7:10 AM
americanbankingnews.com logo$7.5 Million in Sales Expected for Arbutus Biopharma Corp (ABUS) This Quarter
www.americanbankingnews.com - April 29 at 9:51 AM
americanbankingnews.com logoArbutus Biopharma Corp (ABUS) Earning Somewhat Favorable Media Coverage, Study Shows
www.americanbankingnews.com - April 27 at 9:32 AM
americanbankingnews.com logo Brokerages Expect Arbutus Biopharma Corp (ABUS) Will Post Earnings of -$0.30 Per Share
www.americanbankingnews.com - April 27 at 9:08 AM
streetinsider.com logoArbutus Biopharma (ABUS) Presents ARB-1467 Data Presentation ... - StreetInsider.com
www.streetinsider.com - April 24 at 3:18 PM
americanbankingnews.com logoArbutus Biopharma Corp (ABUS) Earning Somewhat Favorable News Coverage, Report Finds
www.americanbankingnews.com - April 24 at 11:45 AM
streetinsider.com logoArbutus Biopharma (ABUS) Presents ARB-1467 Data Presentation at EASL
www.streetinsider.com - April 24 at 11:14 AM
globenewswire.com logoArbutus Announces ARB-1467 Data Presentation at EASL - GlobeNewswire (press release)
globenewswire.com - April 22 at 10:58 AM
finance.yahoo.com logoArbutus Announces ARB-1467 Data Presentation at EASL
finance.yahoo.com - April 22 at 10:57 AM
americanbankingnews.com logoArbutus Biopharma Corp (ABUS) Getting Favorable Press Coverage, AlphaOne Reports
www.americanbankingnews.com - April 20 at 7:31 AM
americanbankingnews.com logoArbutus Biopharma Corp (ABUS) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 18 at 1:47 PM
americanbankingnews.com logoArbutus Biopharma Corp (ABUS) Given Media Sentiment Score of 0.22
www.americanbankingnews.com - April 17 at 9:18 AM
americanbankingnews.com logoArbutus Biopharma Corp (ABUS) Getting Somewhat Critical Press Coverage, Analysis Shows
www.americanbankingnews.com - April 14 at 1:06 PM
globenewswire.com logoArbutus Injunction Survives Attempted Appeal by Acuitas Nasdaq ... - GlobeNewswire (press release)
globenewswire.com - April 13 at 3:32 PM
finance.yahoo.com logoArbutus Injunction Survives Attempted Appeal by Acuitas
finance.yahoo.com - April 13 at 3:32 PM
finance.yahoo.com logoArbutus Injunction Survives Attempted Appeal by Acuitas
finance.yahoo.com - April 13 at 3:32 PM
americanbankingnews.com logoArbutus Biopharma Corp (ABUS) Stock Rating Upgraded by Chardan Capital
www.americanbankingnews.com - April 8 at 7:21 PM
americanbankingnews.com logoZacks: Analysts Anticipate Arbutus Biopharma Corp (ABUS) Will Announce Earnings of -$0.30 Per Share
www.americanbankingnews.com - April 6 at 12:19 AM
americanbankingnews.com logoShort Interest in Arbutus Biopharma Corp (ABUS) Rises By 6.4%
www.americanbankingnews.com - April 4 at 3:00 PM
americanbankingnews.com logoWedbush Reiterates Outperform Rating for Arbutus Biopharma Corp (ABUS)
www.americanbankingnews.com - March 28 at 10:02 AM
americanbankingnews.com logoQ1 2017 EPS Estimates for Arbutus Biopharma Corp (ABUS) Lifted by Analyst
www.americanbankingnews.com - March 27 at 9:46 AM
finance.yahoo.com logoARBUTUS BIOPHARMA CORP Financials
finance.yahoo.com - March 25 at 3:16 PM
streetinsider.com logoArbutus Biopharma (ABUS) Appoints Daniel Burgess to Board of Directors - StreetInsider.com
www.streetinsider.com - March 24 at 3:17 PM
biz.yahoo.com logoARBUTUS BIOPHARMA CORP Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - March 24 at 3:17 PM
americanbankingnews.com logoLeerink Swann Comments on Arbutus Biopharma Corp's Q3 2017 Earnings (ABUS)
www.americanbankingnews.com - March 24 at 11:10 AM
americanbankingnews.com logoAnalysts Offer Predictions for Arbutus Biopharma Corp's Q1 2017 Earnings (ABUS)
www.americanbankingnews.com - March 24 at 9:17 AM
streetinsider.com logoArbutus Biopharma (ABUS) Appoints Daniel Burgess to Board of Directors
www.streetinsider.com - March 24 at 1:28 AM
americanbankingnews.com logoArbutus Biopharma Corp to Post Q1 2017 Earnings of ($0.38) Per Share, Leerink Swann Forecasts (ABUS)
www.americanbankingnews.com - March 23 at 9:17 AM
seekingalpha.com logoArbutus Biopharma's (ABUS) CEO Mark Murray on Full Year 2016 Results - Earnings Call Transcript
seekingalpha.com - March 22 at 8:20 PM
americanbankingnews.com logoArbutus Biopharma Corp (ABUS) Rating Reiterated by Wedbush
www.americanbankingnews.com - March 22 at 4:19 PM
finance.yahoo.com logoEdited Transcript of ABUS earnings conference call or presentation 21-Mar-17 6:00pm GMT
finance.yahoo.com - March 22 at 3:17 PM
biz.yahoo.com logoARBUTUS BIOPHARMA CORP Files SEC form 10-K, Annual Report
biz.yahoo.com - March 22 at 3:17 PM
americanbankingnews.com logoArbutus Biopharma Corp (ABUS) PT Lowered to $9.00 at Wedbush
www.americanbankingnews.com - March 22 at 2:52 PM
finance.yahoo.com logoArbutus Announces Year-End 2016 Financial Results
finance.yahoo.com - March 21 at 8:10 AM
biz.yahoo.com logoARBUTUS BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition
biz.yahoo.com - March 21 at 8:10 AM
biz.yahoo.com logoARBUTUS BIOPHARMA CORP Files SEC form 8-K/A, Entry into a Material Definitive Agreement
biz.yahoo.com - March 20 at 3:32 PM

Social

Chart

Arbutus Biopharma Corp (ABUS) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by MarketBeat.com Staff